Phase 3 Lymphoma Trial, Recruiting NCT07366801 Sponsor: Federal Research Institute of Pediatric Hematology, Oncology and Immunology Condition: Lymphoma
Back to Lymphoma

Phase 3 Lymphoma Trial, Recruiting

NCT07366801
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 0 to 25 years who, along with their legal representative if under 18 (or the patient themselves if aged 14 to 25), have signed a consent form to take part
  • People for whom a bone marrow or stem cell transplant from a donor has been recommended by their medical team, in line with current medical guidelines
  • People whose planned stem cell transplant would use a donor who is a partial genetic match (such as a parent or child), rather than a full match
  • People whose general health and ability to perform daily activities is rated above 70% on a standard medical scale (meaning broadly able to care for themselves)
  • People with a life expectancy of at least 8 weeks
  • People whose heart is pumping well enough, with a pumping function of at least 40% as measured by a heart scan
  • People who agree to attend follow-up appointments for 3 years after the trial

Who may not be able to join:

  • People with an active (acute) hepatitis virus infection or a new HIV infection
  • People whose blood oxygen levels are too low (below 90%) (confirm with trial site)
  • People with significantly elevated bilirubin levels in their blood — more than 3 times the normal limit (confirm with trial site)
  • People with significantly elevated creatinine levels in their blood — more than 3 times the normal limit, indicating reduced kidney function (confirm with trial site)
  • People who are pregnant or currently breastfeeding
  • People who have a life-threatening infection at the time of enrolment
  • People with serious conditions affecting the brain or nervous system, such as epilepsy, dementia, or significant brain damage (confirm with trial site, as the original criteria note some uncertainty around this)
  • People whose general health and daily functioning is rated below 70% on the standard medical scale used in the inclusion criteria

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +79166512145

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Registry
ClinicalTrials.gov
Start date
3 September 2025
Est. completion
1 June 2027

Where this trial is recruiting

🇷🇺 Russia

Primary endpoints

Feasibility- Number of participants with treatment-related adverse events as assessed by CTCAE v4.0; Safety- Number of participants with treatment-related adverse events as assessed by CTCAE v4.0

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov